HomeNVO • NYSE
add
Novo Nordisk A/S
$38.02
Makalipas ang Oras ng Trabaho:(0.053%)-0.020
$38.00
Sarado: Mar 12, 7:59:38 PM GMT-4 · USD · NYSE · Disclaimer
Nakaraang pagsara
$38.83
Sakop ng araw
$37.85 - $39.02
Sakop ng taon
$35.85 - $82.57
Market cap
128.86B USD
Average na Volume
27.56M
P/E ratio
10.66
Dividend yield
4.89%
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (DKK) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 79.14B | -7.63% |
Gastos sa pagpapatakbo | 29.73B | 12.96% |
Net na kita | 26.89B | -4.74% |
Net profit margin | 33.98 | 3.13% |
Kita sa bawat share | 6.04 | -4.73% |
EBITDA | 36.66B | -23.44% |
Aktuwal na % ng binabayarang buwis | 21.34% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (DKK) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 26.96B | 2.49% |
Kabuuang asset | 542.90B | 16.60% |
Kabuuang sagutin | 348.86B | 8.29% |
Kabuuang equity | 194.05B | — |
Natitirang share | 4.44B | — |
Presyo para makapag-book | 0.89 | — |
Return on assets | 16.70% | — |
Return on capital | 29.56% | — |
Cash Flow
Net change in cash
| (DKK) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 26.89B | -4.74% |
Cash mula sa mga operasyon | 7.62B | -38.06% |
Cash mula sa pag-invest | -42.81B | 53.07% |
Cash mula sa financing | 29.47B | -20.00% |
Net change in cash | -5.62B | 86.41% |
Malayang cash flow | -34.95B | -1,011.09% |
Tungkol
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
Itinatag
Dis 21, 1923
Headquarters
Website
Mga Empleyado
69,150
